End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.29 MYR | +2.81% | +10.03% | +32.13% |
Apr. 15 | Apex Healthcare Berhad Proposes the Special Dividend for the Financial Year Ended 31 December 2023 | CI |
Feb. 22 | Apex Healthcare Boosts Dividend Despite Profit Decline in Q4 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company benefits from high valuations in earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+32.13% | 496M | - | ||
+17.35% | 71.39B | C+ | ||
+2.39% | 25.1B | C+ | ||
-1.22% | 8.59B | C | ||
+6.69% | 8.19B | B | ||
-20.96% | 7.91B | B- | ||
-0.18% | 4.54B | B- | ||
+17.12% | 4.31B | B+ | ||
-2.61% | 3.86B | B | ||
+22.08% | 3.64B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- AHEALTH Stock
- Ratings Apex Healthcare